PMID- 17825811
OWN - NLM
STAT- MEDLINE
DCOM- 20080205
LR  - 20221207
IS  - 0009-9120 (Print)
IS  - 0009-9120 (Linking)
VI  - 40
IP  - 16-17
DP  - 2007 Nov
TI  - Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from 
      patients with type 2 diabetes mellitus.
PG  - 1232-9
AB  - OBJECTIVE: To determine the effect of methylglyoxal (MG) on cytokine production 
      by, and apoptosis of, neutrophils from type 2 diabetes mellitus (T2DM) patients. 
      DESIGN AND METHODS: The levels of plasma MG, cytokines released by isolated 
      neutrophils and the apoptotic status of neutrophils were determined. RESULTS: The 
      higher level of plasma MG in T2DM patients was correlated positively with 
      glycated hemoglobin levels, fasting plasma glucose levels and urine 
      albumin/creatinine ratios. The basal levels of cytokines released from 
      neutrophils were markedly higher in patients. MG treatment of the neutrophils 
      isolated from diabetic patients either did not alter, or decreased, the 
      production of cytokines. In contrast, MG induced the release of cytokines from 
      neutrophils of non-diabetics. Moreover, the neutrophils from T2DM patients showed 
      a greater proclivity for apoptosis, which was further increased by in vitro MG 
      treatment. CONCLUSION: MG stimulated neutrophils to release more cytokines, which 
      might play a role in the development of infection in T2DM.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Pharmacology, University of Saskatchewan, Saskatoon, 107 Wiggins 
      Road, Canada S7N 5E5.
FAU - Meng, Qing H
AU  - Meng QH
FAU - Gordon, John R
AU  - Gordon JR
FAU - Khandwala, Hasnain
AU  - Khandwala H
FAU - Wu, Lingyun
AU  - Wu L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070811
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Cytokines)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 722KLD7415 (Pyruvaldehyde)
RN  - EC 3.4.22.- (Caspase 3)
RN  - MU72812GK0 (Creatine)
SB  - IM
MH  - Aged
MH  - Albuminuria/urine
MH  - Anti-Inflammatory Agents/blood/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Blood Glucose/metabolism
MH  - Caspase 3/blood
MH  - Creatine/urine
MH  - Cytokines/blood
MH  - Diabetes Mellitus, Type 2/*blood/pathology/urine
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Interleukin-6/blood
MH  - Interleukin-8/blood
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/*drug effects/metabolism/pathology
MH  - Nitric Oxide/blood
MH  - Pyruvaldehyde/blood/*pharmacology
MH  - Tumor Necrosis Factor-alpha/blood
EDAT- 2007/09/11 09:00
MHDA- 2008/02/06 09:00
CRDT- 2007/09/11 09:00
PHST- 2007/04/24 00:00 [received]
PHST- 2007/07/05 00:00 [revised]
PHST- 2007/07/19 00:00 [accepted]
PHST- 2007/09/11 09:00 [pubmed]
PHST- 2008/02/06 09:00 [medline]
PHST- 2007/09/11 09:00 [entrez]
AID - S0009-9120(07)00302-5 [pii]
AID - 10.1016/j.clinbiochem.2007.07.016 [doi]
PST - ppublish
SO  - Clin Biochem. 2007 Nov;40(16-17):1232-9. doi: 10.1016/j.clinbiochem.2007.07.016. 
      Epub 2007 Aug 11.